Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Pegylated interferon α-2a (Peg-IFN-α) represents a therapeutic alternative to the prolonged use of nucleos(t)ide analog (NA) in chronic hepatitis B (CHB) infection. The mechanisms leading to a positive clinical outcome remain unclear. As immune responses are critical for virus control, we investigat...
Main Authors: | Juliana Bruder Costa, Tania Dufeu-Duchesne, Vincent Leroy, Inga Bertucci, Magali Bouvier-Alias, Noelle Pouget, Ophelie Brevot-Lutton, Marc Bourliere, Fabien Zoulim, Joel Plumas, Caroline Aspord, ANRS HB06 PEGAN study group |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4922676?pdf=render |
Similar Items
-
Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection.
by: Caroline Aspord, et al.
Published: (2016-01-01) -
Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
by: Zhenhuan Cao, et al.
Published: (2020-10-01) -
B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.
by: Zhenhuan Cao, et al.
Published: (2020-01-01) -
Recombinant HBsAg Vaccine in Persons with HIV: Is Seroconversion Sufficient for Long-term Protection?
by: Powis, Jeff
Published: (2010) -
Recombinant HBsAg Vaccine in Persons with HIV: Is Seroconversion Sufficient for Long-term Protection?
by: Powis, Jeff
Published: (2010)